Compare Novartis AG (NVS) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Novartis AG trades at $152.73 (market cap $295.37B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.42. The key difference: Novartis AG pays a 3.07% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VWO | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | — |
52-Week High | $168.62 | $61.24 |
52-Week Low | $119.31 | $51.20 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
VWO trades at $60.49, up 0.27% with a bullish technical signal from moving averages. The ETF shows strong institutional accumulation with multiple advisors increasing positions recently. Emerging markets are experiencing record capital inflows as investors diversify beyond US stocks, with VWO offering low-cost exposure to developing economies at a 0.06% expense ratio.
The outlook remains positive given institutional support and emerging market momentum, though risks include China's weighting impact and potential volatility. VWO's low expense ratio and 2.4% dividend yield provide competitive advantages over peers like EEM (0.69% fee) for emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
